禁煙のためのニコチン置換療法(NRT)と迷走神経刺激を併用した研究
禁煙のためのニコチン置換療法(NRT)と迷走神経刺激の併用
The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.
調査の概要
状態
条件
詳細な説明
This study will evaluate the role of vagal nerve stimulation as a potential adjunct to nicotine patches to help smokers stop smoking.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Sara Seegmiller, M.A.N, R.N
- 電話番号:507-538-7820
- メール:NicotineRes@mayo.edu
研究連絡先のバックアップ
- 名前:Donna K Lawson
- 電話番号:507-255-7975
- メール:NicontineRes@mayo.edu
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic in Rochester
-
主任研究者:
- Ivana T Croghan, PhD
-
主任研究者:
- Ryan T Hurt, MD, PhD
-
コンタクト:
- Shawn Fokken, CCRP
- 電話番号:507-538-7820
- メール:RSTGIMRESStudies@mayo.edu
-
コンタクト:
- Sara Seegmiller, RN
- 電話番号:507-538-7820
- メール:RSTGIMRESStudies@mayo.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 years of age or older at the time of consent.
- Currently smoking cigarettes on a regular basis
- Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above);
- Ability to participate fully in all aspects of the study.
- Have the ability to provide informed consent.
- Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators.
Exclusion Criteria:
-
Patients with a current moderate/severe depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9).
-
Patients who are or have used an investigational drug within the past 30 days.
-
Patients who are currently using medication(s) known to interact with varenicline.
-
Patients who have clinically significant acute/chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease.
-
Patients with a known allergy to nicotine patches or varenicline.
-
Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and/or severe gastrointestinal disease such as gastroparesis.
-
Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device.
-
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
-
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
-
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
-
Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck
-
Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).
-
Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded.
- Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations.
- Specifically, the study does not include fetuses, neonates, pregnant women, children (<18 years of age), prisoners, institutionalized individuals, or other vulnerable populations.
i. All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Vagal Nerve Stimulator and Nicotine Replacement Patches
This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It), as well as the vagal nerve stimulator (VNS) device to use during these 12 weeks while trying to stop smoking. The VNS delivers up to 30 stimulations over 24 hours. |
VNS is a handheld, rechargeable, portable device that delivers electrical signals to the vagal nerve when positioned on the skin of the neck at the appropriate location to stimulate the vagal nerve for 2 minutes at each treatment. During these 12 weeks, participants will also use a 21 mg nicotine patch daily.
他の名前:
|
|
アクティブコンパレータ:Nicotine Replacement Patches
This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It). |
Use of a 21 mg nicotine patch daily for up to 12 weeks
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Smoking Abstinence
時間枠:week 12
|
reporting smoking abstinence and having it be biochemically confirmed (CO reading of < 8 ppm) |
week 12
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ivana T Croghan, PhD、Mayo Clinic
- 主任研究者:Ryan T Hurt, MD, PhD、Mayo Clinic
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 25-005696
- 1R21CA302802-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。